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Summary Photodynamic therapy consists of the systemic administration of a derivative of haematoporphyrin
(Photofrin 11) followed 24-72 h later by exposure of malignant lesions to photoradiation. We investigated the
efficacy of this treatment after direct intratumoral injection of Photofrin II. This direct treatment regimen
resulted in higher rates of inhibition of mitochondrial cytochrome c oxidase (5.13% J' cmM2 x 10-') and
succinate dehydrogenase (3.14% J-' cm-2 X 10- I) in vitro at 2 h after intratumoral injection compared to rates
of inhibition obtained after intraperitoneal drug administration: 0.51 and 0.42% J -I cm-2 x 10-', respectively.
A significant delay in tumour growth in vivo was observed in animals that received intratumoral injections 2 h
before photoradiation compared to animals injected intraperitoneally at either 2 or 24 h before photoradiation.
The treatment protocols were compared with control groups, consisting of Photofrin II administration
intratumorally or intraperitoneally without photoradiation, or photoradiation in the absence of Photofrin II.
These data indicate that the intratumoral injection regimen with Photofrin II enhanced the efficacy of
photodynamic therapy. The greater delay in tumour growth observed after intratumoral administration of
Photofrin II suggests a mechanism favouring direct cell damage.
Photodynamic therapy (PDT), a promising therapeutic
modality for the management of various types of malignan-
cies, employs a combination of the systemic administration of
a photosensitiser (Photofrin II) with the direct exposure of
tumours to visible irradiation, a protocol that results in
metabolic inhibition of malignant cells in vitro and in vivo
(Hilf et al., 1986, 1987; Kessel, 1986; Ceckler et al., 1986).
The photosensitised damage is attributed to production of
the highly reactive oxygen species, singlet oxygen, which is
formed upon exposure of the porphyrin components in
Photofrin II to visible light (Weishaupt et al., 1976; Gibson
et al., 1984a; Parker, 1987). Two features of PDT are
noteworthy. The hydrophobic components (Dougherty, 1987;
Kessel et al., 1987) of Photofrin II (presumably di-haema-
toporphyrin ethers and/or esters) are retained for longer
periods in tumour tissue than in most normal tissues (Gomer
& Dougherty, 1979; Kostron et al., 1986; Steichen et al.,
1986; Lin et al., 1988a), resulting in a favourable tumour to
normal tissue ratio of photosensitiser. By creating a
therapeutic window at selected times after drug administra-
tion, irradiation would produce minimal deleterious effects in
the surrounding normal tissues due to their reduced por-
phyrin content. The second feature of PDT is the ability to
deliver focused visible light energy via laser fibre optics, thus
providing a precise tumour treatment. The typical clinical
PDT protocol consists of the systemic administration of
2-5 mg kg-' Photofrin 11 followed 24-72 h later by
exposure of malignant lesions to 50-400 J cm-2 visible
photoradiation, usually 630 nm laser emission. Utilising these
treatment conditions for various types of malignancies,
encouraging clinical results have been reported (Kato et al.,
1986; Lam et al., 1987; Gilson et al., 1988; Nseyo et al., 1987;
McCaughan et al., 1988). Any improvement in the efficacy of
PDT should increase its acceptance as a useful cancer treat-
ment.
Some additional information has been reported recently to
improve PDT by modifying the standard treatment protocol.
Lin et al. (1988b) compared effects of PDT after injecting
Photofrin II directly into the tumour versus intraperitoneal
injection. Although they found no significant difference in the
response of a murine bladder tumour, assessed by measuring
cell survival in vitro, they suggested that the effects observed
may occur by different mechanisms, i.e. induction of vascular
damage after i.p. administration versus direct cytotoxicity
after intratumoral injection (Lin et al., 1988b). However,
Kostron et al. (1986) found an increased efficacy for PDT
after intratumoral injection in a rodent glioma. We con-
ducted studies to modify the standard PDT protocol in seek-
ing to increase its efficacy for treatment of a transplantable
rodent mammary adenocarcinoma. Data presented here dem-
onstrate that intratumoral administration of Photofrin II
increases the efficacy of PDT in this mammary tumour
model.
Materials and methods
Materials
All chemicals were purchased from Sigma Chemical Co. (St
Louis, MO, USA) unless otherwise noted. Photofrin II,
generously provided by Quadra Logic Technologies Inc.
(Vancouver, British Columbia, Canada), was received frozen,
thawed at room temperature in the dark, divided into 1 ml
aliquots, and stored at -70°C until used.
Animals and tumours
The R3230AC mammary adenocarcinoma was maintained by
transplantation into the axillary region of 80-100 g female
Fischer rats, using the sterile trochar method described
earlier (Hilf et al., 1965).
In vivo -in vitro protocol
Photofrin II was administered to tumour-bearing rats, either
systemically by intraperitoneal (i.p.) injection or by intra-
tumoral (i.t) inoculation. Each injection was followed by an
equilibration period of either 2 or 24 h, during which time
tumour-bearing animals were housed in the dark. Intra-
tumoral injections employed in the in vivo-in vitro protocol
were, depending on the required injection volume, performed
with either a 1 ml disposable syringe (> 50 ,.I) or a Hamilton
syringe (< 50 rd), each fitted with a 27 gauge 5/8 inch needle.
The needle was inserted laterally at the tumour midline and
positioned approximately at the centre of the tumour, where
the Photofrin II was injected. Initial tumour volumes before
administration of Photofrin II i.t. or i.p. ranged from 0.79 to
2.56 cm3 allowing for a sufficient amount of tissue for
preparation of mitochondria. Animals bearing tumours were
selected randomly for either i.t. or i.p. administration of
Photofrin II, each treatment group consisting of animals with
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tumours having volumes spanning the above stated range.
Photofrin II concentrations administered i.t. were adjusted to
attain equivalent body weight (b.w.) doses of 0.25, 0.5, 2.5 or
5.0 mg kg-' for the dose studies and 5.0 mg kg-' for the i.t.
versus i.p. comparative studies. The upper limit of tumour
volume, 2.56cm3, used in these studies represents tumours
that measured less than 1.5 cm maximum diameter. Based on
previous microscopic and magnetic resonance imaging studies
of this mammary tumour model, the extent of necrosis in this
range is estimated to be less than 10% of tumour volume and
is usually focal in nature; it was not thought to alter
significantly either the distribution or clearance of the
injected Photofrin II. The animals were killed at selected
times, tumours and livers were surgically excised in dimmed
room light, and suspensions of mitochondria were prepared
from whole tissues and stored in I ml aliquots at -70°C
until assayed (Gibson & Hilf, 1983).
Photoradiation ofmitochondrial suspensions in vitro
One ml aliquots of tumour or liver mitochondrial suspen-
sions were removed from storage, thawed at room
temperature and adjusted to the desired initial enzyme
activity by dilution with preparation buffer (see below) before
photoradiation of the suspensions in vitro. One ml aliquots of
these suspensions were exposed to photoradiation emitted
from a filtered (570-700 nm) focused quartz halogen light
source. The samples placed in 3 ml quartz cuvettes were
positioned in the 1 cm diameter focussed beam and irradiated
with a power density of 150 mW cm-2, measured by a power
radiometer (Model Rk 5200, Laser Precision, Utica, NY,
USA) connected to an Rk 545 radiometer probe. The suspen-
sions were stirred magnetically and, at selected times, samples
(10-40 jd) were removed for analysis of enzyme activity.
Temperature of the suspensions, which was monitored during
the irradiation period (1 h, 540 J cm-2 total fluence), did not
rise above ambient (25°C).
Enzyme activity analysis
The activities of cytochrome c oxidase and succinate
dehydrogenase were analysed at various intervals during the
in vitro exposure of the mitochondrial suspensions to
photoradiation. Before photoradiation, liver or tumour
suspensions were adjusted to selected initial enzyme activities
by dilution with the preparation buffer (0.33 M sucrose, 1 mM
dithiothreitol, 1 mM EGTA, 0.03% bovine serum albumin
and 100 mMKCI); these activities were 0.4-0.61mol cyto-
chrome c oxidised per min per mg protein for cytochrome c
oxidase and 4.6-8.3 x 10-2mmol p-iodonitrotetrazolium
violet (INT) oxidised per min per mg protein for succinate
dehydrogenase.
Laser photoradiation oftumours in vivo
Tumours, borne on host animals administered Photofrin II,
were photoradiated after reaching a size of 0.4-0.9 cm2 sur-
face area (calculated from two opposing diagonal caliper
measurements), which corresponded to a volume range of
0.18-0.54 cm3 (see below) and a final drug dose of
0.81-1.55 mg kg-' body weight (b.w.). Animals were appor-
tioned to each treatment group to provide similar tumour
size ranges. The tumour volumes employed in this aspect,
involving tumour growth behaviour in vivo, were smaller
than those used above in the in vivo-in vitro protocol.
Smaller tumours could be used since it was not necessary to
obtain large amounts of tissue for subsequent preparation of
subcellular organelles. Further, as tumour size increases,
PDT is less effective, presumably due to insufficient light
penetration resulting in cytotoxicity only in the outermost
regions of the lesion. The tumours were exposed to a 1 cm
diameter beam emitted from a fibre optic cable fitted with a
cylindrical lens and coupled to an argon pumped tunable dye
laser (Coherent, Palo Alto, CA, USA). Power density inci-
dent on the tumours was adjusted to 200 mWcm-2 as
measured using a power radiometer (RK5200, Laser
Precision, Utica, NY, USA).
Tumour volume determinations and examination oftreatment
efficacy
Tumour volume was calculated according to V =r2nH, where
the width, r, and the length, H, were obtained with calipers.
The actual tumour volume was assessed by measuring the
water displacement for the whole tumour, and comparing
such values with volumes calculated by caliper measurements
on the same tumour before its removal from the host.
Estimation of volume by use of the equation yielded an
average over-estimate of 25% for a cohort of six represen-
tative tumours whose volume was obtained by displacement
measurements. Nevertheless, growth of each tumour was fol-
lowed by caliper measurement and the increase in calculated
tumour volume is presented as the number of days required
for each tumour to reach 2, 5 or 10 times its initial volume.
Analyses of the data using designated increments in tumour
volume provide a more consistent basis for comparison
among groups, particularly when initial tumour volumes, i.e.
start of treatment, could vary (usually ±20%) and the initial
treatment may have begun at different days after tumour
implantation.
Statistical analysis
Tukey's multiple comparison procedure (Snedecor & Coch-
ran, 1967) was used to assess significant differences in tumour
volume; changes from initial to 2 times initial volume, and
from 2 times initial to 10 times initial volume were compared.
A value of P<0.05 was considered to be significant.
Results
Effects ofPhotofrin II inducedphotosensitisation on
mitochondrial enzyme activities in vitrofollowing intratumoral
drug administration
Photofrin II, administered i.p., results in a dose dependent
inhibition of tumour mitochondrial cytochrome c oxidase
and succinate dehydrogenase (SDH) during in vitro exposure
of mitochondrial suspensions to visible irradiation (Gibson et
al., 1989). Here we examined whether such a dose relation-
ship existed after Photofrin II was administered intra-
tumorally (i.t.). Two hours before killing, Photofrin II was
administered i.t. at doses equivalent to 0.25, 0.5, 2.5 or
5.0 mg kg', and mitochondria prepared from tumour and
liver were exposed to photoradiation (see Materials and
methods). The data for cytochrome c oxidase (Figure 1) are
presented to demonstrate that both a drug-dose and light-
dose relationship existed for the inhibition of this enzyme
and for SDH (not shown), in mitochondria prepared from
tumours that were injected i.t. with Photofrin II 2 h before
killing. Liver mitochondria prepared from the same animals
also displayed dose-related inhibitions of both of these
enzymes, but at this 2 h time point the extent of inhibition of
liver enzymes was considerably less than that observed in
tumours (data not shown). The rates of inhibition, calculated
as per cent enzyme inhibition per joule per cm2, which were
derived from the linear initial portion of the inhibition curves
as in Figure 1, are compiled in Table I. The increases in the
enzyme inhibition rates were drug-dose dependent, displaying
linearity in tumours for i.t. doses up to 2.5 mg kg-' b.w. and
for liver up to 5.0 mg kg-' b.w., results suggesting that a
maximum tumour porphyrin level was reached by direct
injection. A comparison between tumour and liver mitochon-
drial preparations, at 2 h after i.t. injection, demonstrated
that liver was 5-10-fold less susceptible to photosensitisation
for each dose of Photofrin II administered. We interpret
these results to indicate that higher concentrations of por-
phyrin were present in tumour tissue at this time, rather than
inherent differences in enzyme sensitivity in these two tissues.INTRATUMORAL ADMINISTRATION OF PHOTOFRIN II 555
co
,.r_
cJ
0
a) (n
x
0
0
a)
E
20
0
0
s
0 300 600
J/cm2
Figure I Effects of intratumoral injection of Photofrin II on
inhibition of mitochondrial enzymes in vitro. Tumour mitochon-
dria were prepared 2 h after i.t. administration of Photofrin II at
0.25 (0,), 0.5 (A) , 2.5 (0) or 5.0 (U) mg kg-' b.w. and
photoradiated in vitro with broad band light (570-700 nm) at a
power dose of 150 mWcm-'. The data are expressed as per cent
of initial enzyme activity (zero time before photoradiation) for
cytochrome c oxidase in the tumour. Each data point represents
the mean of four separate experiments performed in duplicate;
error bars are the s.e.m.
Liver and tumour mitochondria from untreated animals were
prepared, incubated with Photofrin II in vitro, resuspended in
buffer after removal of Photofrin II solution and
photoradiated. No difference was observed in the photo-
induced rate of inhibition of either cytochrome c oxidase or
SDH present in either preparation, demonstrating that there
were no inherent differences in enzyme sensitivity attributable
to tissue source.
Comparison ofintraperitoneal versus intratumoral
administration ofPhotofrin II on the activities ofmitochondrial
enzymes in vitro
Photofrin II (5 mg kg-' b.w.) was administered either i.p. or
i.t. at 2 or 24 h before killing of tumour-bearing animals and
preparation of mitochondria. The data obtained for the
Table I Rates of enzyme inhibition in vitro following i.t.
administration of Photofrin II in vivo
Photofrin Cytochrome c oxidase Succinate dehydrogenase
dose (mgkg-') Tumour Liver Tumour Liver
0.25 1.18±.06 0.30±.014 1.00±.06 0.39±.035
0.50 1.45±.08 0.36±.037 1.37±.13 0.42±.024
2.50 4.24±.36 0.57±.05 2.70±.36 0.66±.054
5.00 5.13±.37 0.94±.07 3.14±.22 0.74±.091
Photofrin II was administered by direct tumour injection at various
doses: 0.25,0.5, 2.5 or 5.0 mg kg-' b.w. Tumourand livermitochondria
were prepared 2 h after Photofrin II administration and exposed to
broad band illumination (570-700 nm) at a power dose of
150 mWcm-2. Rates of enzyme inhibition were calculated from the
linearportion oftheinhibition curves in Figure 1. Ratesareexpressed as
percent enzyme inhibition JI' cm-2 and are presented as means +
s.e.m. Initial activities (0 light) were adjusted by dilution of
mitochondria and were: cytochrome c oxidase, 0.4-0.61jmol
cytochrome c oxidised per min per mg protein; succinate
dehydrogenase, 4.6-8.3 x 10-2 tmol p-iodonitrotetrazolium violet
oxidised per min per mg protein.
photoradiation-induced inhibition of cytochrome c oxidase
and SDH in tumour and liver preparations in vitro, presented
as the calculated rates of enzyme inhibition, are compiled in
Table II. The data clearly demonstrate that photosensitised
inhibition of tumour mitochondrial enzymes in vitro 2 h after
administration of Photofrin II i.t. was much greater than that
observed after i.p. administration (5.45 v. 0.51% and 3.98 v.
0.45% inhibition J-' cm-2 x 10-' for cytochrome c oxidase
and succinate dehydrogenase, respectively). At 2 h, the liver
mitochondrial enzymes also demonstrated a greater enzyme
inhibition rate for i.t. v. i.p. drug admininstration. In tumour
preparations obtained at 24 h post-injection, i.t. administra-
tion of Photofrin 11 continued to be more effective in causing
photosensitised inhibition of both enzymes compared to i.p.
injection. However, for the liver preparations, obtained 24 h
after drug administration, a difference in response of cyto-
chrome c oxidase and SDH relative to route of administra-
tion of photosensitiser was no longer apparent.
Comparison ofeffects ofintratumoral versus intraperitoneal
Photofrin II administration on tumour growth
Tumour growth was assessed in both treated and untreated
animals by determination of tumour volume at regular inter-
vals after tumours became palpable. Analyses of these data,
presented as time in days necessary to attain 2, 5 or 10 times
initial volume, are displayed in Figure 2. Intratumoral
Photofrin 1I was administered at a dose of 0.5mgcm-3,
which represented a range of 0.81-1.55 mg kg-' b.w. Statis-
tical analysis of the data depicted in Figure 2, using Tukey's
multiple comparison procedure, indicates that Photofrin II at
0.5 mg cm3 tumour i.t. or at 10mg kg-' i.p. caused a statis-
tically significant delay of tumour growth when compared to
tumour growth in animals injected i.t. with Photofrin II or
10 mg kg -' i.p. but not irradiated (dark controls). This delay
in tumour growth in those animals receiving i.t. Photofrin II
Table II Comparison ofratesofmitochondrial enzymeinhibition followingeitheri.p. or
i.t. administration of Photofrin 11
2h 24h
Enzyme Tissue i.t. ip. i.t. ip.
Cytochrome c Tumour 5.13±0.37 0.51 ±0.034 1.11 ±0.07 0.66±0.09
nxidn-,e
Succinate
Liver 0.94± 0.07 0.21 ± 0.013 0.94±0.11 0.72±0.06
Tumour 3.14± 0.22 0.42±0.05 2.12± 0.09 1.09± 0.04
aenyurogenas Liver 0.74±0.09 0.29±0.016 0.67±0.05 0.85±0.084
Photofrin II was administered either i.p. or i.t. at 5 mgkg-' b.w. at 2 or 24 h before
preparation and exposure oftumour orliver mitochondria to irradiation. Photoradiation
wasperformed asdescribed in the Methods. Ratesofenzyme inhibition werederived from
the linearportion oftheinhibition curvesdisplayed in Figure2. Rates areexpressed asper
cent enzyme inhibition J-I cm2 x 10' and are presented as means ± s.e.m. Initial
activities (0 light) were the same as listed in Table I.
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Figure 2 The effects ofi.t. v. i.p. Photofrin II administration on
R3230AC tumour growth. Tumours were injected directly with
Photofrin II and not exposed to photoradiation (U), or injected
i.t. 2 h (A) or 24 h (0) before light exposure in vivo. Comparison
was made to tumours borne on animals injected i.p. with
10 mg kg-' i.p. 2 h before photoradiation (A). In vivo
photoradiation conditions are described in the Methods. Data are
expressed as time, in days, required for tumours to attain 2, 5 or
10 times their initial volume, based on measurements obtained
before any treatment. Each data point represents the mean
tumour volume obtained from six or more tumours; error bars
are the s.e.m.
(irradiation 2 h after injection) continued during the period
that tumour volume increased from 2 to 10 times initial size
(P = 0.05 v. all other groups). However, the other PDT
regimens (Photofrin II administered at 0.5 mg cm-3 tumour
i.t. 24 h before irradiation or at 10 mg kg-' i.p. 2 h before
irradiation) did not significantly alter tumour growth during
the latter tumour growth period. Tumours borne on animals
that had not received Photofrin II (light control) were
irradiated with a total fluence of 360 Jcm-2
(200mWcm-2 30 min-') and demonstrated no alteration in
tumour growth when compared to untreated controls. Intra-
tumoral temperature measurements were obtained under the
above conditions, using a Model 41TD telethermometer (Yel-
low Springs Instruments, Yellow Springs, OH, USA) con-
nected to a needle probe; the intratumoral temperature did
not rise above 39°C. The data represented graphically in
Figure 2 demonstrate that the 2 h interval between drug
administration i.t. and photoradiation was signficantly more
effective in producing delay of tumour growth.
Discussion
Although combinations of PDT with other treatment
modalities, such as X-irradiation (Bellnier & Dougherty,
1986; Winther et al., 1988; Levendag et al., 1989),
chemotherapy using adriamycin (Edell & Cortese, 1988),
cisplatin or doxorubicin (Nahabedian et al., 1988), hyperther-
mia by combining PDT with microwave irradiation (Waldow
& Dougherty, 1984; Waldow et al., 1987; Levendag et al.,
1989) and the use of hypoxic cell sensitisers, e.g.
misonidazole (Gonzalez et al., 1986; Winther et al., 1988),
have been reported, the results have been inconsistent. Less
attention has been given to exploring modification of the
commonly used PDT protocol so as to improve its efficacy.
A number of variables can be investigated including: (i)
increasing the concentrations of photosensitiser in neoplastic
tissue to give a higher tumour/normal tissue ratio; (ii) light
delivery, which optimally should provide sufficient and
uniform photon flux throughout the neoplastic tissue; and
(iii) adequate oxygen concentrations for production of singlet
oxygen throughout the irradiation schedule. Our laboratory
and others have begun to address the first of these com-
ponents, delivery of photosensitiser. Zhou et al. (1988)
administered haematoporphyrin that was incorporated into
liposomes or was bound to lipoproteins of various density to
improve the uptake of photosensitiser by tumour tissue after
systemic admininstration. With both modified delivery
vehicles, tumour response to PDT was more rapid and cell-
directed than seen after conventional injection. In several
earlier reports (Kostron et al., 1986; Lin et al., 1988a, b), a
direct injection of HpD into tumours was used so as to
increase the efficacy of PDT as well as investigate the
mechanisms of cell cytotoxicity and tumour regression.
Although a transplantable rodent glioma demonstrated a
greater responsiveness when HpD was administered i.t. (Kos-
tron et al., 1986), response of the mouse MBT-2 bladder
tumour was not enhanced, even though 5-10 times more
porphyrin was present in tumours after i.t. injection (Lin et
al., 1988 a, b). Perhaps tumour type and/or host species
could account for such apparent differences in response.
In this report, we compared the effects of two routes of
drug administration on photosensitisation of mitochondria
and on tumour growth after PDT. For study of mitochon-
drial effects, the in vivo-in vitro protocol was employed, an
approach that takes into account any host metabolism and
intracellular localisation of the photosensitiser occurring in
vivo (Gibson & Hilf, 1983; Gibson et al., 1984b, 1989). From
such data, we can derive an estimate of the pharmacokinetics
of the administered photosensitiser. Previously, after i.p.
administration of either HpD or PhotofrinII, a time course
of photosensitivity of these organelles in vitro indicated that
inhibition of mitochondrial function would be greatest when
tumours were exposed to light 24-72 h after drug adminis-
tration (Gibson et al., 1989). Intratumoral administration of
PhotofrinII, however, showed a different time-course. At 2 h
after i.t. administration, we observed a 10-fold greater rate of
photosensitiser-induced inhibition of tumour mitochondrial
enzymes than that observed in comparable mitochondrial
preparations after animals had received equivalent doses of
Photofrin II (5 mg kg- ') intraperitoneally. By 24 h after
Photofrin II administration, such differences in photosen-
sitivity of enzymes narrow considerably, with only 2-fold
greater sensitivity for i.t. than for i.p. routes. These results
imply that there were higher concentrations of Photofrin II in
tumours shortly after i.t. administration, whereas after i.p.
administration, the level of porphyrin at 2 or 24 h, based on
mitochondrial enzyme inhibition, was largely unchanged.
A different pattern of photosensitisation of liver mitochon-
dria was observed. Surprisingly, liver mitochondria displayed
greater photosensitivity at 2 h after i.t. administration than
after i.p. injection, as evidenced by the light-induced inhibi-
tion of cytochrome c oxidase and SDH activities. This
finding suggests that after direct injection into the tumour,
more effective levels of drug reached the liver via the systemic
circulation than after i.p. injection. One possbile explanation
for this observation might be attributed to the presence of
multimeric aggregates versus dimeric and monomeric
haematoporphyrin species reaching the liver from the
peritoneal injection site. While all of these forms after tissue
extraction contribute to the amount of drug measured
chemically, not all forms give equal singlet oxygen yields
upon photoirradiation (Lambert et al., 1986). In contrast, at
24 h, liver mitochondrial enzymes were more photosensitive
than at 2 h after i.p. injection, suggesting a greater accumula-
tion and/or a slower efflux of active forms of the photosen-
sitiser. A more extensive study of distribution of photosen-
sitiser in other normal tissues after i.t. injection is warranted.
The results obtained from examination of mitochondrial
enzyme inhibition, using the in vivo-in vitro protocol, were
correlatable to effects of PDT on delay of tumour growth.
No significant effects on tumour growth occurred in animals
that received Photofrin II (i.p. at 10mg kg-' or i.t. at
1 mg kg-' b.w.) but were not photoradiated (dark controls),
nor in animals that received no drug but light (light con-
trols). In contrast, tumours in animals given Photofrin II i.t.
at 1 mg kg-' b.w. and irradiated either at 2 or 24 h later
displayed a significant delay in the length of time required toINTRATUMORAL ADMINISTRATION OF PHOTOFRIN II 557
double their initial tumour volume. Most interesting is the
finding that subsequent tumour growth, i.e. the time required
to increase from 2 times initial size to 10 times initial size,
was significantly longer in animals that received i.t. Photofrin
II 2 h before light exposure. Mitochondria from tumours of
these animals displayed the greatest photosensitivity, imply-
ing that the greatest metabolic damage could occur under
these conditions. However, vascular damage cannot be ex-
cluded as a contributing factor in retarding tumour growth;
photosensitivity of liver mitochondria indicates efflux of some
i.t. administered drug from the tumour into the systemic
circulation. Because prolonged tumour growth retardation
was not evident with the other treatment protocols employed,
we suggest that vascular damage alone could not be the
cause of the observed persistent tumour growth retardation
following i.t. injection 2 h before irradiation. Regardless of
the mechanism, the data presented demonstrate that intra-
tumoral administration of Photofrin II provides one app-
roach to enhance the effectiveness of PDT on tumour
growth.
Although, clinically, lesions may not be accessible or are
too numerous to treat by i.t. injections of Photofrin II, there
are instances where superficial lesions could be treated by this
method of drug delivery. The possibility also exists that, in
such cases, the lower amounts of i.t. Photofrin II would
result in less skin photosensitivity. Studies directed towards
assessing these possibilities are in progress.
This study was supported by USPHS Grant CA36856, National
Institutes of Health. We acknowledge the assistance of Kim Gabriel
of the Animal Tumor Research Facility, University of Rochester
Cancer Center (CA11198), for maintenance of the R3230AC mam-
mary carcinoma. We are grateful for the gift of Photofrin 11 from
Quadra Logic Technologies, Vancouver, BC, Canada.
References
BELLNIER, D.A. & DOUGHERTY, T.J. (1986). Haematoporhyrin
derivative photosensitization and radiation damage interaction in
chinese hamster ovary fibroblast. Int. J. Radiat. Biol., 50, 659.
CECKLER, T.L., BRYANT, R.G., PENNEY, D.P., GIBSON, S.L. & HILF,
R. (1986). 3'P-NMR spectroscopy demonstrates decreased ATP
levels in vivo as an early response to photodynamic therapy.
Biochem. Biophys. Res. Commun., 140, 273.
DOUGHERTY, T.J. (1987). Studies on the structure of porphyrins
contained in photofrin II. Photochem. Photobiol., 46, 569.
EDELL, E.S. & CORTESE, D.A. (1988). Combined effects of
hematoporphyrin derivative phototherapy and adriamycin in a
murine tumor model. Lasers Surg. Med., 8, 413.
GIBSON, S.L., COHEN, H.J. & HILF, R. (1984a). Evidence against the
production of superoxide by photoirradiation of hematopor-
phyrin derivative. Photochem. Photobiol., 40, 441.
GIBSON, S.L. & HILF, R. (1983). Photosensitization of mitochondrial
cytochrome c oxidase by hematoporphyrin derivative and related
porphyrins in vitro and in vivo. Cancer Res., 43, 4191.
GIBSON, S.L., LEAKEY, P.B., CRUTE, J.J. & HILF, R. (1984b).
Photosensitization of mitochondrial cytochrome c oxidase by
hematoporphyrin derivative (HpD) in vitro and in vivo. In Por-
phyrin Localization and Treatment of Tumors, Dorion, D.R. &
Gomer, C.J. (eds) p. 323. Alan R. Liss: New York.
GIBSON, S.L., MURANT, R.S., CHAZEN, M.D., KELLY, M.E. & HILF,
R. (1989). In vitro photosensitisation of tumour cell enzymes by
photofrin II administered in vivo. Br. J. Cancer, 59, 47.
GILSON, D., ASH, D., DRIVER, I., FEATHER, J.W. & BROWN, S.
(1988). Therapeutic ratio of photodynamic therapy in the treat-
ment of superficial tumours of skin and subcutaneous tissue in
man. Br. J. Cancer, 58, 60.
GOMER, C.J & DOUGHERTY, T.J. (1979). Determination of [3H] and
['4C] hematoporphyrin derivative distribution in malignant and
normal tissue. Cancer Res., 39, 146.
GONZALEZ, S., ARNFIELD, M.R., MEEKER, B.E. & 4 others (1986).
Treatment of Dunning R3327-AT rat prostate tumors with
photodynamic therapy in combination with misonidazole. Cancer
Res., 46, 2858.
HILF, R., GIBSON, S.L., PENNEY, D.P., CECKLER, T.L. & BRYANT,
R.G. (1987). Early biochemical responses to photodynamic
therapy monitored by NMR spectroscopy. Photochem.
Photobiol., 46, 809.
HILF, R., MICHEL, I., BELL, C., FREEMAN, J.J. & BORMAN, A.
(1965). Biochemical and morphological properties of a new lac-
tating tumor line in the rat. Cancer Res., 25, 286.
HILF, R., MURANT, R.S., NARAYANAN, U. & S.L. GIBSON (1986).
Relationship of mitochondrial function and cellular adenosine
triphosphate levels to hematoporphyrin derivative induced
photosensitization in R3230AC mammary tumors. Cancer Res.,
46, 211.
KATO, H., KONAKA, C., KAWATE, N. & 5 others (1986). Five year
disease-free survival of a lung cancer patient treated only by
photodynamic therapy. Chest, 90, 769.
KESSEL, D. (1986). Sites of photosensitization by derivatives of
hematoporphyrin. Photochem. Photobiol., 44, 489.
KESSEL, D., THOMPSON, P., MUSSELMAN, B. & CHANG, C.K.
(1987). Chemistry of hematoporphyrin-derived photosensitizers.
Photochem. Photobiol., 46, 563.
KOSTRON, H., BELLNIER, D.A., LIN, C.W., SWARTZ, M.R. &
MARTUZA, R.L. (1986). Distribution, retention and phototoxicity
of hematoporphyrin derivative in a rat glioma. J. Neurosurg., 64,
768.
LAM, S., MULLER, N.L., MILLER, R.R. & 6 others (1987). Laser
treatment of obstruction endobronchial tumors: factors which
determine response. Lasers Surg. Med., 7, 29.
LAMBERT, C.R., REDDI, E., SPIKES, J.D., RODGERS, M.A.J. & JORI,
G. (1986). The effects of porphyrin structure and aggregation on
photosensitized processes in aqueous and micellar media.
Photochem. Photobiol., 44, 595.
LEVENDAG, P.C., RUIFROK, A.C.C., MARIJNISSEN, J.P.A., VANPAT-
TEN, W.L.J. & VISSER, A.G. (1989). Preliminary experience with
interstitial radiation, interstitial hyperthermia and interstitial
photodynamic therapy in a simple animal model. Strahlenther.
Onkologie, 165, 56.
LIN, C-W., AMANO, T., RUTLEDGE, A.R. & SHULOK, J.R. (1988a).
HPD Administration by intra-tumor injection: distribution,
photodynamic effects and utilities. In Advances in
Photochemotherapy, Hasan, T. (ed.) p. 22. SPIE Proceedings.
LIN, C.-W., AMANO, T., RUTLEDGE, H.R., SHULOK, J.R. & PROUT,
G.R. (1988b). Photodynamic effect in an experimental bladder
tumor treated with intratumor injection of hematoporphyrin
derivative. Cancer Res., 48, 6115.
McCAUGHAN, J.S., HAWLEY, P.C., BETHEL, B.H & WALKER, J.
(1988). Photodynamic therapy of endobronchial malignancies.
Cancer, 62, 691.
NAHABEDIAN, M.Y., COHEN, R.A., CONTINO, M.F. & 4 others
(1988). Combination cytotoxic chemotherapy with cisplatin or
doxorubicin and photodynamic therapy in murine tumors. J.
Natl Cancer Inst., 80, 73.
NSEYO, U.O., DOUGHERTY, T.J. & SULLIVAN, L. (1987).
Photodynamic therapy in the management of resistent lower
urinary tract carcinoma. Cancer, 60, 3113.
PARKER, J.G. (1987). Optical monitoring of singlet oxygen genera-
tion during photodynamic treatment of tumors. IEEE Circuits
and Devices Magazine, January, 10.
SNEDECOR, G.W. & COCHRAN, W.G. (1967). Statistical Methods, 6th
edn. Iowa State Univ. Press: Ames, IA.
STEICHEN, J.D., DASHNER, K. & MARTUZA, R.L. (1986). Distribu-
tion of hematoporphyrin derivative in canine glioma following
interneoplastic and intraperitoneal injection. J. Neurosurg., 65,
364.
WALDOW, S.M & DOUGHERTY, T.J. (1984). Interaction of hyper-
thermia and photoradiation therapy. Radiat. Res., 97, 380.
WALDOW, S.M., HENDERSON, B.W. & DOUGHERTY, T.J. (1987).
Hyperthermic potentiation of photodynamic therapy employing
photofrin I and II: comparison of results using three animal
tumor models. Lasers Surg. Med., 7, 12.
WEISHAUPT, K.R., GOMER, C.J. & DOUGHERTY, T.J. (1976).
Identification of singlet oxygen as the cytotoxic agent in
photoinactivation of a murine tumor. Cancer Res., 36, 2322.
WINTHER, J., OVERGAARD, J. & EHLERS, N. (1988). The effect of
photodynamic therapy alone and in combination with
misonidazole or X-rays for management of a retinoblastoma-like
tumor. Photochem. Photobiol., 47, 419.
ZHOU, C., MILANESI, C. & JORI, G. (1988). An ultrastructural com-
parative evaluation of tumors photosensitized by porphyrins
administered in aqueous solution, bound to liposomes or to
lipoproteins. Photochem. Photobiol., 48, 487.